Long-term Immunogenicity of the 13-valent Pneumococcal Conjugate Vaccine during Adjuvant Chemotherapy in Patients with Gastric and Colorectal Cancer: A 5-Year Follow-up of a Randomized Controlled Trial

Hyeon-Jong Kim; Hyunjin Bang; Hyun-Jung Shim; Jun Eul Hwang; Sang-Hee Cho; Ik-Joo Chung; Seung Ji Kang; Jong Gwang Kim; Seung-Hoon Beom; A-Yeung Jang; Joon Young Song; Woo Kyun Bae

doi:10.4143/crt.2024.1083

Articles

Page Path: HOME > Cancer Res Treat > Volume 58(1); 2026 > Article

Original Article General Long-term Immunogenicity of the 13-valent Pneumococcal Conjugate Vaccine during Adjuvant Chemotherapy in Patients with Gastric and Colorectal Cancer: A 5-Year Follow-up of a Randomized Controlled Trial: Hyeon-Jong Kim¹, Hyunjin Bang¹, Hyun-Jung Shim¹, Jun Eul Hwang¹, Sang-Hee Cho¹, Ik-Joo Chung¹, Seung Ji Kang², Jong Gwang Kim³, Seung-Hoon Beom⁴, A-Yeung Jang^5,6, Joon Young Song^5,6, Woo Kyun Bae¹; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2026;58(1):61-70.
DOI: https://doi.org/10.4143/crt.2024.1083
Published online: February 12, 2025

¹Division of Hematology-Oncology, Department of Internal Medicine, Chonnam National University Medical School and Hwasun Hospital, Hwasun, Korea

²Division of Infectious Diseases, Department of Internal Medicine, Chonnam National University Medical School and Hwasun Hospital, Hwasun, Korea

³Department of Hematology/Oncology, School of Medicine, Kyungpook National University, Daegu, Korea

⁴Division of Medical Oncology, Department of Internal Medicine, Yonsei University of College of Medicine, Seoul, Korea

⁵Division of Infectious Disease, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea

⁶Vaccine Innovation Center-KU Medicine (VIC-K), Seoul, Korea

Correspondence: Woo Kyun Bae, Division of Hematology-Oncology, Department of Internal Medicine, Chonnam National University Medical School and Hwasun Hospital, 322 Seoyang-ro, Hwasun 58128, Korea
Tel: 82-61-379-7623 E-mail: drwookyun@jnu.ac.kr

Co-correspondence: Joon Young Song, Division of Infectious Disease, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, 148 Gurodong-ro, Guro-gu, Seoul 08308, Korea
Tel: 82-2-2626-3052 E-mail: infection@korea.ac.kr

• Received: November 12, 2024 • Accepted: February 11, 2025

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

6,035 Views
151 Download

prev next

Full Article

Download PDF

Abstract

Purpose
Current guidelines recommend vaccination at least 2 weeks before chemotherapy initiation to optimize the immune response despite limited evidence. Our previous study indicated no differences in short-term immune response for the 13-valent pneumococcal conjugate vaccine (PCV13) according to the vaccination timing. This study aims to investigate the long-term efficacy of PCV13 and clinical factors associated with the respective antibody response.
Materials and Methods
Patients with gastric or colorectal cancer who received adjuvant chemotherapy were enrolled and divided into two groups: vaccinated 2 weeks before chemotherapy (arm A) and vaccinated concurrently with chemotherapy (arm B). Serum samples were collected before vaccination and in one month, 3 years, and 5 years. Immune responses were measured using enzyme-linked immunosorbent assay and multiplex opsonophagocytosis assay.
Results
Including 63 patients, both groups showed an initial increase in the geometric mean titers of opsonophagocytic activity and the geometric mean concentrations of serotype-specific IgG levels after one month, followed by a decline at 3 and 5 years, particularly for serotypes 1, 14, 18C, and 19A. Despite the decline, global protection was maintained for 5 years, although global response decreased. The two arms did not show significant differences in immunogenicity nor in factors such as vaccination timing, age, cancer type, or chemotherapy regimen.
Conclusion
Vaccination timing is not a significant factor for the immunogenicity of PCV13 in cancer patients undergoing adjuvant chemotherapy. Global protection against pneumococcal infection was sustained for > 5 years, and global response remained in over half of patients.
Key words: Pneumococcal vaccines, Chemotherapy, Adjuvant, Stomach neoplasms, Colorectal neoplasms

Introduction

Pneumonia accounts for nearly 10% of cancer patients’ hospitalizations, with bacterial pneumonia significantly contributing to morbidity and mortality in this population [1]. In immunocompromised patients, the pathogens responsible for community-acquired pneumonia (CAP) are often detected at prevalences similar to those in immunocompetent individuals, with pneumococcus being the most common pathogen among cancer patients [2]. Furthermore, pneumococcal vaccination reduces pneumonia incidence, decreases hospitalization, and improves clinical outcomes in cancer patients [3].

Current guidelines recommend pneumococcal vaccination for immunocompromised individuals, including cancer patients, to prevent pneumococcal infections. The Infectious Diseases Society of America developed clinical practice guidelines in 2013, advocating for pneumococcal vaccination in immunocompromised individuals, including cancer patients receiving chemotherapy [4]. Similarly, the U.S. Advisory Committee on Immunization Practice recommends pneumococcal conjugate vaccines for adults aged ≥ 65 years, as well as for individuals aged 6-64 years with altered immunocompetence [5]. Numerous oncology practice guidelines, including those from the National Comprehensive Cancer Network and the American Society of Clinical Oncology, have adopted these recommendations and suggest using the pneumococcal conjugate vaccine for pneumococcal vaccine–naïve newly diagnosed cancer patients [6,7]. However, the optimal timing for vaccination remains uncertain. Existing guidelines suggest vaccination before initiating chemotherapy to optimize an immune response. However, the evidence is primarily limited to patients with severe humoral immunity impairment, such as those with chronic lymphocytic leukemia receiving rituximab or Bruton Tyrosine Kinase inhibitors [7].

Previously, we investigated the impact of vaccination timing with the 13-valent pneumococcal conjugated vaccine (PCV13) in patients with colorectal and gastric cancer undergoing adjuvant chemotherapy [8]. Our initial study found that the interval between vaccination and chemotherapy did not significantly influence immunogenicity and antibody response [8]. However, the study only assessed short-term post-vaccination outcomes. A long-term follow-up was needed to identify the trend in antibody response and the potential need for revaccination after completing chemotherapy. Therefore, this follow-up study aims to further evaluate the long-term immunogenicity of PCV13 in these patients and identify factors associated with the respective antibody response.

Materials and Methods

1. Patients and study design

Patients from the previous study who agreed to long-term follow-up and repeat blood sampling were enrolled in this follow-up study. All subjects had undergone curative resection for gastric or colorectal cancer and completed an adjuvant chemotherapy course. The PCV13 was administered to all patients who were divided into two groups: arm A received the vaccine 2 weeks before chemotherapy, and arm B received it on the first day of chemotherapy. Serum samples were collected at baseline and in one month, 3 years, and 5 years after vaccination. Additionally, data on the incidence of invasive pneumococcal infections or pneumonia were gathered through follow-up assessments.

2. Immunogenicity

As in the previous study, the serologic response was evaluated using a multiplex opsonophagocytosis assay (MOPA) for serotypes 5, 6B, 18C, and 19A, which were selected based on the nasopharyngeal carriage rate and invasive disease potential. The assay was conducted using follow-up samples. Geometric mean titers, fold increase of titers, the seroprotection rate (percentage of patients with post-vaccination opsonophagocytic activity [OPA] titer ≥ 1:64), and the seroconversion rate (percentage of patients with ≥ 4-fold increase in OPA titers) were used to assess the immunogenicity.

Additionally, antibody responses to all 13 serotypes in PCV13 were measured using an enzyme-linked immunosorbent assay (ELISA). Global protection (IgG concentration ≥ 1 μg/mL for at least five PCV13 tested serotypes) and global response (at least a two-fold increase, compared to the baseline, in specific IgG antibody levels for at least five PCV13 tested serotypes) were also used to evaluate the immune response to the vaccine [9-14].

3. Protocol of ELISA and MOPA

The MOPA assay was conducted to estimate the level of functional antibodies against four selected pneumococcal serotypes. The titer of OPA was defined as the serum dilution ratio that killed 50% of bacteria. A detailed MOPA assay protocol is posted online at http://www.vaccine.uab.edu. Briefly, frozen aliquots of S. pneumoniae (streptomycin-resistant-serotype 5, spectinomycin-resistant serotype 6B, optochin-resistant serotype 18C, and trimethoprim-resistant serotype 19A) were washed twice. Then, 10 μL of the serially diluted serum and pneumococcal mixture were added to 96-well plates and incubated for 30 minutes with gentle shaking (700 rpm). Afterward, 40 μL of HL60 cells (1×10⁷ cells/mL) and 10 μL of baby rabbit complement (Pel-Freez Biological) were added to each well. The plate was incubated in a 5% CO₂ incubator at 37ºC for 45 minutes with shaking (700 rpm) and transferred to ice for 20 minutes. Afterward, 10 μL of the final reaction mixture was spotted on four different THY agar plates. Then, THY with 0.75% agar and 2,3,4-triphenyl tetrazolium chloride (TTC; Sigma-Aldrich) as an overlay agar containing one of the four antibiotics was added to each plate and incubated overnight at 37ºC. Bacterial colonies were counted using the National Institute of Standards and Technology (NIST)-developed NIST’s Integrated Colony Enumerator software.

Pneumococcal ELISA was performed to measure the polysaccharide serotype-specific IgG titers as previously described (http://www.vaccine.uab.edu). The immunoplates (SPL) were coated with 100 μL/well of polysaccharide (5 μg/mL, ATCC) in the phosphate-buffered saline (PBS) and incubated at 37ºC for 5 hours. The coated plates were stored at 4°C overnight and washed 3 times with PBS containing 0.05% Tween 20 (PBS-T; Sigma-Aldrich). The sera were diluted using the adsorption solution by adding 5 μg/mL of cell wall polysaccharide (Statens Serum Institut) and 22F capsular polysaccharide (ATCC) to PBS-T. The adsorbed sera were serially 2-fold diluted in PBS-T on the washed plates and incubated for 2 hours at room temperature. After washing, the plates were incubated for 2 hours at room temperature with goat anti-human IgG-alkaline phosphatase conjugate (Southern Biotech). Then, the plates were washed 5 times with PBS-T, followed by adding 100 μL/mL of AP substrate reagent (1 mg/mL p-nitrophenyl phosphate in the diethanolamine substrate buffer). When the color changed, 50 μL of 3 N NaOH was added as a stop solution. The absorbance was read at 405 nm (test wavelength) and 690 nm (reference wavelength) using a microplate reader (Molecular Devices). Data were analyzed using the standardized curve-fit four-parameter logistic method (4-PL) in the pneumococcal ELISA manual.

4. Statistical analysis

Categorical variables, analyzed using the chi-squared test (or Fisher exact test as appropriate), are presented as numbers and percentages. Continuous variables, analyzed using the Mann-Whitney U test, are presented as medians and ranges. OPA titers and specific IgG concentrations by ELISA are expressed as geometric means with 95% confidence intervals (CIs). Geometric mean titers (GMTs), their mean fold increases, and geometric mean concentrations (GMCs) of specific IgG titers were analyzed using the Student’s t test. Factors associated with global protection and global response were analyzed using a logistic regression model, with results expressed as odds ratio and 95% CIs. SPSS ver. 26.0 (IBM Corp.) was used for all statistical analyses. A p-value < 0.05 indicated statistical significance.

Results

1. Patients characteristics

Among the 92 patients enrolled in the previous study, 63 participated in this long-term follow-up study. Arm A comprised 29 patients, while arm B included 34 patients. Baseline characteristics, including age, sex, Eastern Cooperative Oncology Group performance status, cancer stage, cancer type, and chemotherapeutic regimen, did not significantly differ between the two arms (Table 1). All participants in both groups completed their standard adjuvant chemotherapy courses.

2. Immunogenicity assays

1) Geometric mean titers of OPA

For the four serotypes, the GMTs of OPA significantly increased one month after vaccination. Although GMTs decreased over time, they remained above the pre-vaccination levels. No significant difference was observed between the arms (Table 2).

2) Fold increase in post-vaccination GMTs of OPA

The fold increase in GMTs peaked one month after vaccination, with most values decreasing to below half in 3 years (Table 3). However, GMTs were stabilized between 3 and 5 years post-vaccination. Additionally, no significant difference in fold increase was noted between the arms (Table 3).

3) Seroprotection and seroconversion based on the OPA

One month after vaccination, seroprotection rates exceeded 80% for all four serotypes. For serotypes 6B, 18C, and 19A, seroprotection rates consistently remained above 80% in both arms. In contrast, seroprotection rates for serotype 5 decreased to around 50% in both arms (Fig. 1A, S1 Table). Similar to our previous study, seroconversion rates varied significantly depending on the serotypes. Contrary to the seroprotection rate results, seroconversion rates for serotype 5 were higher compared to other serotypes, remaining sustained after 5 years (Fig. 1B, S1 Table). No significant differences in seroprotection and seroconversion were observed between the two arms.

4) Geometric mean concentration of specific IgG titers

Among the 13 pneumococcal serotypes, specific IgG titers significantly increased after vaccination for all serotypes, except for serotype 3. GMCs for serotypes 1, 6B, 7F, 14, 18C, and 19A decreased by > 50% after 3 years. GMCs for serotypes 4, 5, 6A, 9V, 19F, and 23F were maintained or showed a slow decline in three and 5 years. Comparing both arms, only the GMC for serotype 4 at one month was significantly different (arm A vs. B, 1.46 [95% CI, 0.94 to 2.26] vs. 2.49 [95% CI, 1.96 to 3.15]; p=0.041). GMCs for other serotypes were similar at 3 and 5 years between both arms (Table 4, S2 Fig.).

5) Global protection and global response

Global protection rates were higher than the pre-vaccination level at 90% (arm A vs. B, 91.7% vs. 96.3%; p=0.575). In arm B, all patients met the criteria for global protection after vaccination, which was consistently maintained even after 5 years. Although some patients in arm A did not meet the criteria, most had global protection, showing no significant difference between the two groups. Conversely, global response rates were the highest one month after vaccination and then continued to decline. More than half of patients in both groups maintained their global response to vaccination. No significant difference was observed between both arms in the global response across all periods (Table 5).

Logistic regression analyses were conducted to assess the impact of each factor on global protection and global response. Timing of vaccination (2 weeks before vs. the same day), age, sex, cancer site (gastric cancer vs. colorectal cancer), performance status, cancer stage (I-II vs. III-IV), and the type of chemotherapy regimen (monotherapy vs. doublet chemotherapy) had no significant impact on global protection and global response following PCV13 vaccination across all periods (Table 6).

3. Cases of pneumococcal infections

No cases of invasive pneumococcal diseases or pneumococcal pneumonia were identified among the study participants throughout the follow-up.

Discussion

Our previous study demonstrated that PCV13 immunogenicity is adequate in patients with gastric and colorectal cancer undergoing adjuvant chemotherapy [8]. Contrary to the general recommendations suggesting delayed vaccination during chemotherapy, we found that the antibody response to PCV13 in cancer patients receiving the vaccine concurrently with chemotherapy was not inferior to those who were vaccinated 2 weeks before starting chemotherapy [8]. To the best of our knowledge, this is the first study conducting a 5-year follow-up of PCV13 vaccination in patients with solid tumors undergoing chemotherapy. This study reaffirms that the timing of vaccination relative to chemotherapy does not significantly influence PCV13 immunogenicity in this patient population. Additionally, PCV13 demonstrates sustained immunogenicity over 5 years, with global protection maintained in most patients.

The MOPA analysis demonstrated significant rises in GMTs and fold increases in functional antibodies for four serotypes one month after vaccination. Although GMTs declined after 5 years, they remained higher than the pre-vaccination levels. Furthermore, ELISA results for all subtypes showed remarkable immunogenicity in cancer patients receiving chemotherapy. Jackson et al. [15] reported PCV13 immunogenicity in immunocompetent and pneumococcal vaccine–naïve patients using OPA assays one month after PCV13 vaccination. Their results were comparable to those of our immunocompromised cohort [15]. In another study involving immunocompetent adults (B1851020 Study Group, NCT00521586), OPA and ELISA analyses were performed one month and 5 years after vaccination. While some antibody titers in our study were lower than in that study, most titers were comparable [16]. Hence, PCV13 demonstrates sustained immunogenicity, effectively protecting against invasive pneumococcal disease even in patients undergoing adjuvant chemotherapy.

Despite the high global protection rates observed for 5 years, the pre-vaccination global protection rates in this study were already over 90%. The concept of global protection, commonly used in studies involving immunocompromised patients [10-14], may require reassessment as a reliable measure of immunogenicity. Actually, unlike in children, the serotype-specific protective threshold of the pneumococcal vaccine has not been established in adults [17]. Over time, the global response rates declined, although more than half of the patients still demonstrated a global response 5 years after vaccination. Therefore, PCV13 immunogenicity diminishes over time, particularly for pneumococcal serotypes 1, 14, 18C, and 19A, which exhibited a marked decline in antibody levels after 3 and 5 years. Given the invasive potential of these serotypes, the observed decline raises the question of whether revaccination is necessary to maintain protection in this population.

Patient factors, such as age, sex, and performance status, did not influence immunogenicity. Additionally, contrary to previous recommendations, administering the vaccine concurrently with chemotherapy did not impact short- and long-term immunogenicity. This result also supports the recommendation for pneumococcal vaccination in cancer patients regardless of chemotherapy timing. This finding is crucial for simplifying vaccination protocols in solid tumor patients undergoing cytotoxic chemotherapy, allowing them to receive necessary immunizations without delaying their treatment.

However, this study has some limitations. The relatively small sample size (63 patients) and the inclusion of only certain cancer types may limit the generalizability of the findings. Furthermore, the study did not evaluate the impact of newer chemotherapy agents, such as immune checkpoint inhibitors, which could influence vaccine responses by altering the immune response dynamics. Additionally, refining the methodologies used to assess vaccine immunogenicity, such as incorporating more sensitive biomarkers, could better predict the long-term effectiveness of pneumococcal vaccination [18].

Future studies should investigate the optimal timing for revaccination in oncology patients, especially given the observed decline in antibody titers over time, which might affect long-term protection against pneumococcal disease. Additionally, research on various cancer types and differing chemotherapy objectives, such as palliative versus curative intent, could provide a broader understanding of pneumococcal vaccination effectiveness in these populations. Such studies could lead to more tailored vaccination schedules for patients undergoing diverse cancer treatments.

In conclusion, this study demonstrates that PCV13 vaccination induces long-term immunity against vaccine-type pneumococci with the potential to improve vaccine efficacy in patients undergoing adjuvant chemotherapy for gastric and colorectal cancer. Vaccination timing relative to chemotherapy initiation does not significantly impact the long-term immunogenicity of pneumococcal vaccination. However, the gradual decline in antibody levels over time suggests that some patients may require revaccination to maintain adequate protection. Further research is needed to establish the optimal revaccination timing in this vulnerable population.

Electronic Supplementary Material

Supplementary materials are available at Cancer Research and Treatment website (https://www.e-crt.org).

crt-2024-1083_S1_Table.pdf

crt-2024-1083_S2_Fig.pdf

NOTES

Ethical Statement

The institutional review board of Chonnam National University Hwasun Hospital approved this study (CNUHH-2018-171). This trial was conducted following the Declaration of Helsinki, with all patients providing written informed consent.

Author Contributions

Conceived and designed the analysis: Song JY, Bae WK.

Collected the data: Kim HJ, Bang H, Shim HJ, Hwang JE, Cho SH, Chung IJ, Kang SJ, Kim JG, Beom SH, Jang AY, Song JY, Bae WK.

Contributed data or analysis tools: Kim HJ, Jang AY, Song JY, Bae WK.

Performed the analysis: Kim HJ, Jang AY, Song JY, Bae WK.

Wrote the paper: Kim HJ, Kang SJ, Kim JG, Beom SH, Song JY, Bae WK.

Conflicts of Interest

Conflict of interest relevant to this article was not reported.

Funding

This research was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) (NRF-2020M3A9G3080281) and NRF grant (NRF-2020R1A5A2031185) funded by the Korean government (MSIT).

Fig. 1.

Seroprotection (A) and seroconversion (B) rates of arms A and B at 1 month, 3 years, and 5 years after the PCV13 vaccination.

Table 1.

Patients’ characteristics (n=63)

Characteristic	Arm A (n=29)	Arm B (n=34)	p-value
Age (yr)	58.3 (33.2-69.6)	58.9 (29.1-78.9)	0.210
Sex
Male (n=35)	14 (22.2)	21 (33.3)	0.283
Female (n=28)	15 (23.8)	13 (20.6)
ECOG PS
0 (n=15)	9 (14.3)	6 (9.5)	0.214
1 (n=48)	20 (31.7)	28 (44.4)
Stage
I (n=1)	0	1 (1.6)	> 0.99
II (n=21)	10 (15.9)	11 (17.5)
III (n=39)	18 (28.6)	21 (33.3)
IV (n=2)	1 (1.6)	1 (1.6)
Type of cancer
Colorectal cancer (n=52)	21 (33.3)	31 (49.2)	0.093
Gastric cancer (n=11)	8 (12.7)	3 (4.8)
Chemotherapeutic regimen
Fluoropyrimidine (n=15)			0.247
5-Fluorouracil	1 (1.6)	0
Capecitabine	6 (9.5)	6 (9.5)
Tegafur/Gimeracil/Oteracil	2 (3.2)	0
Fluoropyrimidine+oxaliplatin (n=48)
FOLFOX	6 (9.5)	13 (20.6)
CAPEOX	14 (22.2)	15 (23.8)

Values are presented as median (range) or number (%). CAPEOX, capecitabine and oxaliplatin; ECOG PS, Eastern Cooperative Oncology Group performance status; FOLFOX, fluorouracil, leucovorin, and oxaliplatin.

Table 2.

Serial changes of GMTs of MOPA

Serotype	Arm	Pre-vaccination (n=62)			1 Month (n=62)			3 Years (n=59)			5 Years (n=51)
Serotype	Arm	GMT	95% CI	p-value	GMT	95% CI	p-value	GMT	95% CI	p-value	GMT	95% CI	p-value
5	A	6	4-10	0.258	408	165-1,011	0.862	103	39-272	0.544	72	28-188	0.587
	B	4	3-6		369	183-746		72	36-143		53	30-94
6B	A	667	214-2,082	0.960	8,555	5,186-14,113	0.381	3,297	1,763-6,164	0.576	2,713	1,148-6,412	0.912
	B	644	295-1,406		10,930	8,317-14,363		4,102	2,581-6,519		2,866	1,720-4,777
18C	A	115	57-234	0.996	4,672	2,814-7,758	0.716	1,082	564-2,074	0.720	936	425-2,062	0.740
	B	115	51-257		5,422	2,999-9,804		1,293	647-2,582		774	353-1,696
19A	A	535	235-1,216	0.364	7,690	3,874-15,264	0.998	2,018	984-4,142	0.864	1,860	812-4,260	0.692
	B	344	203-583		7,696	5,511-10,747		2,176	1,318-3,592		1,522	862-2,688

CI, confidence interval; GMT, geometric mean titer; MOPA, multiplex opsonophagocytosis assay.

Table 3.

Serial changes of fold increase of MOPA: fold increase in post-vaccination GMTs

Serotype	Arm	1 Month (n=62)			3 Years (n=58)			5 Years (n=50)
Serotype	Arm	Geometric mean fold increase	95% CI	p-value	Geometric mean fold increase	95% CI	p-value	Geometric mean fold increase	95% CI	p-value
5	A	67.8	1.8-2,513.0	0.617	19.1	0.3-1,148.4	0.894	17.2	0.2-1,715.8	0.898
	B	90.4	5.1-1,608.6		17.7	0.7-480.3		16.0	0.6-418.3
6B	A	12.8	0.8-196.1	0.665	7.1	0.5-104.8	0.920	4.2	0.2-76.3	0.896
	B	17.0	2.7-105.0		6.7	0.7-62.7		4.0	0.5-34.4
18C	A	40.6	15.7-104.5	0.808	11.3	3.3-38.7	0.945	11.1	1.4-88.7	0.927
	B	47.2	21.6-103.0		11.8	3.3-42.2		10.4	1.6-68.7
19A	A	14.4	0.4-546.9	0.316	4.8	0.1-246.8	0.615	4.2	0.0-745.5	0.640
	B	22.4	1.0-522.9		6.1	0.1-306.8		5.5	0.0-715.8

CI, confidence interval; GMT, geometric mean titer; MOPA, multiplex opsonophagocytosis assay.

Table 4.

GMCs of specific IgG titers

Serotype	Arm	Pre-vaccination			1 Month			3 Years			5 Years
Serotype	Arm	GMC	95% CI	p-value	GMC	95% CI	p-value	GMC	95% CI	p-value	GMC	95% CI	p-value
1	A	2.24	1.68-2.98	0.340	5.63	3.97-7.99	0.178	0.59	0.45-0.78	0.329	0.65	0.49-0.86	0.663
	B	1.79	1.28-2.52		8.11	5.55-11.84		0.70	0.57-0.87		0.60	0.47-0.76
3	A	0.85	0.64-1.14	0.487	0.43	0.31-0.59	0.935	0.35	0.27-0.45	0.402	0.28	0.23-0.35	0.510
	B	0.75	0.60-0.94		0.44	0.34-0.57		0.40	0.32-0.50		0.31	0.26-0.37
4	A	0.61	0.47-0.80	0.633	1.46	0.94-2.26	0.041	1.50	1.07-2.10	0.978	1.27	0.84-1.91	0.610
	B	0.57	0.47-0.69		2.49	1.96-3.15		1.49	1.20-1.84		1.11	0.85-1.45
5	A	0.56	0.42-0.74	0.536	1.47	0.98-2.20	0.177	3.98	2.56-6.20	0.661	3.78	2.43-5.86	0.735
	B	0.49	0.37-0.65		2.10	1.53-2.87		4.48	3.34-6.01		3.47	2.78-4.35
6A	A	1.34	0.93-1.92	0.681	4.23	2.76-6.49	0.919	5.09	3.50-7.42	0.493	4.74	3.41-6.59	0.923
	B	1.20	0.85-1.70		4.08	2.46-6.78		5.93	4.79-7.34		4.85	3.85-6.11
6B	A	1.16	0.75-1.79	0.826	5.77	3.56-9.34	0.382	2.56	1.55-4.23	0.797	2.16	1.35-3.45	0.529
	B	1.09	0.73-1.62		7.60	5.14-11.24		2.77	2.02-3.80		1.78	1.24-2.57
7F	A	1.87	1.34-2.60	0.727	7.01	4.80-10.24	0.197	2.73	1.95-3.81	0.361	2.42	1.64-3.55	0.515
	B	2.04	1.43-2.90		9.42	7.38-12.01		3.35	2.54-4.42		2.04	1.48-2.81
9V	A	1.95	1.36-2.79	0.421	7.12	4.87-10.39	0.078	6.07	4.28-8.61	0.814	5.60	3.91-8.04	0.698
	B	2.38	1.74-3.25		10.41	8.53-12.69		6.36	5.09-7.95		5.16	4.17-6.39
14	A	13.15	9.46-18.28	0.502	27.70	18.72-41.00	0.865	4.44	3.29-6.00	0.716	4.06	3.04-5.44	0.749
	B	11.35	8.62-14.95		28.87	22.24-37.48		4.81	3.65-6.33		3.80	2.81-5.13
18C	A	4.71	3.86-5.73	0.137	15.62	11.72-20.81	0.269	3.56	2.77-4.58	0.528	2.94	2.10-4.10	0.947
	B	3.86	3.25-4.58		19.37	15.10-24.85		3.95	3.23-4.84		2.99	2.27-3.95
19A	A	10.38	8.03-13.42	0.662	29.76	19.34-45.79	0.253	4.15	2.98-5.78	0.519	3.41	2.25-5.16	0.867
	B	9.61	7.57-12.19		42.70	27.60-66.06		4.81	3.59-6.43		3.57	2.62-4.85
19F	A	1.05	0.80-1.37	0.683	3.60	2.41-5.38	0.272	5.31	3.54-7.97	0.766	4.93	3.14-7.75	0.411
	B	0.97	0.74-1.26		4.91	3.40-7.09		5.76	4.04-8.21		3.85	2.67-5.57
23F	A	0.88	0.60-1.28	0.747	2.75	1.71-4.41	0.150	2.30	1.56-3.39	0.401	2.07	1.44-2.97	0.831
	B	0.96	0.68-1.34		4.21	3.02-5.86		2.82	2.13-3.73		2.17	1.64-2.88

CI, confidence interval; GMC, geometric mean concentration.

Table 5.

Global protection and global response by specific IgG titers

	Arm A	Arm B	p-value
Global protection
Pre-vaccination	22/24 (91.7)	26/27 (96.3)	0.595
1 month	23/24 (95.8)	27/27 (100)	0.471
3 years	24/26 (92.3)	33/33 (100)	0.190
5 years	24/26 (92.3)	27/27 (100)	0.236
Global response
1 month	19/24 (79.2)	25/27 (92.6)	0.232
3 years	12/22 (54.5)	20/26 (76.9)	0.131
5 years	12/21 (57.1)	11/20 (55.0)	> 0.99

Values are presented as number (%).

Table 6.

Factors associated with global protection and global response

Variable	Pre-vaccination			1 Month			3 Years			5 Years
Variable	OR	95% CI	p-value	OR	95% CI	p-value	OR	95% CI	p-value	OR	95% CI	p-value
Factors associated with global protection
Arm B	2.12	0.16 to 27.22	0.566	> 999.99	< 0.01 to > 999.99	0.998	> 999.99	< 0.01 to > 999.99	0.995	> 999.99	< 0.01 to > 999.99	0.995
Age ≥ 65 years	> 999.99	< 0.01 to > 999.99	0.999	1.75	< 0.01 to > 999.99	> 0.99	< 0.01	< 0.01 to > 999.99	0.996	< 0.01	< 0.01 to > 999.99	0.996
Female	0.64	0.05 to 8.38	0.735	> 999.99	< 0.01 to > 999.99	0.998	> 999.99	< 0.01 to > 999.99	0.996	> 999.99	< 0.01 to > 999.99	0.996
Gastric (vs. CRC)	> 999.99	< 0.01 to > 999.99	0.999	0.43	< 0.01 to > 999.99	> 0.99	0.66	< 0.01 to > 999.99	> 0.99	> 999.99	< 0.01 to > 999.99	> 0.99
ECOG PS 1 (vs. 0)	< 0.01	< 0.01 to > 999.99	0.999	< 0.01	< 0.01 to > 999.99	0.999	< 0.01	< 0.01 to > 999.99	0.999	< 0.01	< 0.01 to > 999.99	0.999
Higher stage (vs. I-II)	0.55	0.04 to 8.29	0.666	< 0.01	< 0.01 to > 999.99	0.998	< 0.01	< 0.01 to > 999.99	0.998	< 0.01	< 0.01 to > 999.99	0.998
Doublet chemotherapy	2.24	0.14 to 34.81	0.565	< 0.01	< 0.01 to > 999.99	0.998	< 0.01	< 0.01 to > 999.99	0.998	< 0.01	< 0.01 to > 999.99	> 0.99
Factors associated with global response
Arm B	-	-	-	3.92	0.56 to 27.26	0.168	2.79	0.80 to 9.60	0.106	0.82	0.20 to 3.30	0.778
Age ≥ 65 years	-	-	-	> 999.99	< 0.01 to > 999.99	0.999	0.49	0.07 to 3.39	0.472	1.96	0.29 to 13.42	0.495
Female	-	-	-	3.12	0.41 to 23.91	0.275	1.26	0.27 to 5.98	0.769	0.84	0.20 to 3.55	0.815
Gastric (vs. CRC)	-	-	-	3.17	0.11 to 91.06	0.501	> 999.99	< 0.01 to > 999.99	0.999	1.40	0.10 to 19.89	0.804
ECOG PS 1 (vs. 0)	-	-	-	1.75	0.10 to 32.16	0.706	0.76	0.04 to 14.88	0.856	0.54	0.05 to 6.45	0.625
Higher stage (vs. I-II)	-	-	-	0.72	0.10 to 5.14	0.739	1.40	0.30 to 6.57	0.671	0.37	0.09 to 1.56	0.174
Doublet chemotherapy	-	-	-	0.47	0.40 to 5.46	0.546	0.10	0.01 to 1.12	0.062	1.43	0.21 to 9.80	0.714

CI, confidence interval; CRC, colorectal cancer; ECOG PS, Eastern Cooperative Oncology Group performance status; OR, odds ratio.

REFERENCES

1. Wong JL, Evans SE. Bacterial pneumonia in patients with cancer: novel risk factors and management. Clin Chest Med. 2017;38:263–77. PubMed PMC
2. Di Pasquale MF, Sotgiu G, Gramegna A, Radovanovic D, Terraneo S, Reyes LF, et al. Prevalence and etiology of community-acquired pneumonia in immunocompromised patients. Clin Infect Dis. 2019;68:1482–93. PubMed PMC
3. Chiou WY, Hung SK, Lin HY, Chen LC, Hsu FC, Tsai SJ, et al. Effectiveness of 23-valent pneumococcal polysaccharide vaccine on elderly patients with colorectal cancer: a population-based propensity score-matched cohort study. Medicine (Baltimore). 2019;98:e18380PubMed PMC
4. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:e44–100. Article PubMed PDF
5. Kroger A, Bahta L, Long S, Sanchez P. General best practice guidelines for immunization [Internet]. U.S. Centers for Disease Control and Prevention; 2023. [cited 2024 Nov 11]. Available from: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf
6. National Comprehensive Cancer Network. Prevention and treatment of cancer-related infections (version 3.2024) [Internet]. National Comprehensive Cancer Network; 2024. [cited 2024 Nov 11]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/infections.pdf
7. Kamboj M, Bohlke K, Baptiste DM, Dunleavy K, Fueger A, Jones L, et al. Vaccination of adults with cancer: ASCO guideline. J Clin Oncol. 2024;42:1699–721. PubMed PMC
8. Choi W, Kim JG, Beom SH, Hwang JE, Shim HJ, Cho SH, et al. Immunogenicity and optimal timing of 13-valent pneumococcal conjugate vaccination during adjuvant chemotherapy in gastric and colorectal cancer: a randomized controlled trial. Cancer Res Treat. 2020;52:246–53. Article PubMed PMC PDF
9. Romaru J, Bahuaud M, Lejeune G, Hentzien M, Berger JL, Robbins A, et al. Single-dose 13-valent conjugate pneumococcal vaccine in people living with HIV - immunological response and protection. Front Immunol. 2021;12:791147.Article PubMed PMC
10. Song JY, Cheong HJ, Noh JY, Choi MJ, Yoon JG, Kim WJ. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in HIV-infected adults in the era of highly active antiretroviral therapy: analysis stratified by CD4 T-cell count. Hum Vaccin Immunother. 2020;16:169–75. Article PubMed PMC
11. Bahuaud M, Bodilis H, Malphettes M, Maugard Landre A, Matondo C, Bouscary D, et al. Immunogenicity and persistence of the 13-valent pneumococcal conjugate vaccine (PCV13) in patients with untreated Smoldering Multiple Myeloma (SMM): a pilot study. Heliyon. 2017;3:e00441Article PubMed PMC
12. Lombardi F, Belmonti S, Fabbiani M, Morandi M, Rossetti B, Tordini G, et al. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: a pilot, prospective controlled study. PLoS One. 2016;11:e0156523Article PubMed PMC
13. Robbins A, Bahuaud M, Hentzien M, Maestraggi Q, Barbe C, Giusti D, et al. The 13-valent pneumococcal conjugate vaccine elicits serological response and lasting protection in selected patients with primary humoral immunodeficiency. Front Immunol. 2021;12:697128.Article PubMed PMC
14. Sadlier C, O’Dea S, Bennett K, Dunne J, Conlon N, Bergin C. Immunological efficacy of pneumococcal vaccine strategies in HIV-infected adults: a randomized clinical trial. Sci Rep. 2016;6:32076.Article PubMed PMC PDF
15. Jackson LA, Gurtman A, van Cleeff M, Jansen KU, Jayawardene D, Devlin C, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine. 2013;31:3577–84. Article PubMed
16. Frenck RW Jr, Fiquet A, Gurtman A, van Cleeff M, Davis M, Rubino J, et al. Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older. Vaccine. 2016;34:3454–62. Article PubMed
17. Song JY, Moseley MA, Burton RL, Nahm MH. Pneumococcal vaccine and opsonic pneumococcal antibody. J Infect Chemother. 2013;19:412–25. Article PubMed PMC
18. LaFon DC, Nahm MH. Measuring immune responses to pneumococcal vaccines. J Immunol Methods. 2018;461:37–43. Article PubMed PMC

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Long-term Immunogenicity of the 13-valent Pneumococcal Conjugate Vaccine during Adjuvant Chemotherapy in Patients with Gastric and Colorectal Cancer: A 5-Year Follow-up of a Randomized Controlled Trial

Cancer Res Treat. 2026;58(1):61-70. Published online February 12, 2025

DOI: https://doi.org/10.4143/crt.2024.1083

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
Electronic Supplementary Material
NOTES
REFERENCES

Fig. 1. Seroprotection (A) and seroconversion (B) rates of arms A and B at 1 month, 3 years, and 5 years after the PCV13 vaccination.

Fig. 1.

Characteristic	Arm A (n=29)	Arm B (n=34)	p-value
Age (yr)	58.3 (33.2-69.6)	58.9 (29.1-78.9)	0.210
Sex
Male (n=35)	14 (22.2)	21 (33.3)	0.283
Female (n=28)	15 (23.8)	13 (20.6)
ECOG PS
0 (n=15)	9 (14.3)	6 (9.5)	0.214
1 (n=48)	20 (31.7)	28 (44.4)
Stage
I (n=1)	0	1 (1.6)	> 0.99
II (n=21)	10 (15.9)	11 (17.5)
III (n=39)	18 (28.6)	21 (33.3)
IV (n=2)	1 (1.6)	1 (1.6)
Type of cancer
Colorectal cancer (n=52)	21 (33.3)	31 (49.2)	0.093
Gastric cancer (n=11)	8 (12.7)	3 (4.8)
Chemotherapeutic regimen
Fluoropyrimidine (n=15)			0.247
5-Fluorouracil	1 (1.6)	0
Capecitabine	6 (9.5)	6 (9.5)
Tegafur/Gimeracil/Oteracil	2 (3.2)	0
Fluoropyrimidine+oxaliplatin (n=48)
FOLFOX	6 (9.5)	13 (20.6)
CAPEOX	14 (22.2)	15 (23.8)

Serotype	Arm	Pre-vaccination (n=62)			1 Month (n=62)			3 Years (n=59)			5 Years (n=51)
Serotype	Arm	GMT	95% CI	p-value	GMT	95% CI	p-value	GMT	95% CI	p-value	GMT	95% CI	p-value
5	A	6	4-10	0.258	408	165-1,011	0.862	103	39-272	0.544	72	28-188	0.587
	B	4	3-6		369	183-746		72	36-143		53	30-94
6B	A	667	214-2,082	0.960	8,555	5,186-14,113	0.381	3,297	1,763-6,164	0.576	2,713	1,148-6,412	0.912
	B	644	295-1,406		10,930	8,317-14,363		4,102	2,581-6,519		2,866	1,720-4,777
18C	A	115	57-234	0.996	4,672	2,814-7,758	0.716	1,082	564-2,074	0.720	936	425-2,062	0.740
	B	115	51-257		5,422	2,999-9,804		1,293	647-2,582		774	353-1,696
19A	A	535	235-1,216	0.364	7,690	3,874-15,264	0.998	2,018	984-4,142	0.864	1,860	812-4,260	0.692
	B	344	203-583		7,696	5,511-10,747		2,176	1,318-3,592		1,522	862-2,688

Serotype	Arm	1 Month (n=62)			3 Years (n=58)			5 Years (n=50)
Serotype	Arm	Geometric mean fold increase	95% CI	p-value	Geometric mean fold increase	95% CI	p-value	Geometric mean fold increase	95% CI	p-value
5	A	67.8	1.8-2,513.0	0.617	19.1	0.3-1,148.4	0.894	17.2	0.2-1,715.8	0.898
	B	90.4	5.1-1,608.6		17.7	0.7-480.3		16.0	0.6-418.3
6B	A	12.8	0.8-196.1	0.665	7.1	0.5-104.8	0.920	4.2	0.2-76.3	0.896
	B	17.0	2.7-105.0		6.7	0.7-62.7		4.0	0.5-34.4
18C	A	40.6	15.7-104.5	0.808	11.3	3.3-38.7	0.945	11.1	1.4-88.7	0.927
	B	47.2	21.6-103.0		11.8	3.3-42.2		10.4	1.6-68.7
19A	A	14.4	0.4-546.9	0.316	4.8	0.1-246.8	0.615	4.2	0.0-745.5	0.640
	B	22.4	1.0-522.9		6.1	0.1-306.8		5.5	0.0-715.8

Serotype	Arm	Pre-vaccination			1 Month			3 Years			5 Years
Serotype	Arm	GMC	95% CI	p-value	GMC	95% CI	p-value	GMC	95% CI	p-value	GMC	95% CI	p-value
1	A	2.24	1.68-2.98	0.340	5.63	3.97-7.99	0.178	0.59	0.45-0.78	0.329	0.65	0.49-0.86	0.663
	B	1.79	1.28-2.52		8.11	5.55-11.84		0.70	0.57-0.87		0.60	0.47-0.76
3	A	0.85	0.64-1.14	0.487	0.43	0.31-0.59	0.935	0.35	0.27-0.45	0.402	0.28	0.23-0.35	0.510
	B	0.75	0.60-0.94		0.44	0.34-0.57		0.40	0.32-0.50		0.31	0.26-0.37
4	A	0.61	0.47-0.80	0.633	1.46	0.94-2.26	0.041	1.50	1.07-2.10	0.978	1.27	0.84-1.91	0.610
	B	0.57	0.47-0.69		2.49	1.96-3.15		1.49	1.20-1.84		1.11	0.85-1.45
5	A	0.56	0.42-0.74	0.536	1.47	0.98-2.20	0.177	3.98	2.56-6.20	0.661	3.78	2.43-5.86	0.735
	B	0.49	0.37-0.65		2.10	1.53-2.87		4.48	3.34-6.01		3.47	2.78-4.35
6A	A	1.34	0.93-1.92	0.681	4.23	2.76-6.49	0.919	5.09	3.50-7.42	0.493	4.74	3.41-6.59	0.923
	B	1.20	0.85-1.70		4.08	2.46-6.78		5.93	4.79-7.34		4.85	3.85-6.11
6B	A	1.16	0.75-1.79	0.826	5.77	3.56-9.34	0.382	2.56	1.55-4.23	0.797	2.16	1.35-3.45	0.529
	B	1.09	0.73-1.62		7.60	5.14-11.24		2.77	2.02-3.80		1.78	1.24-2.57
7F	A	1.87	1.34-2.60	0.727	7.01	4.80-10.24	0.197	2.73	1.95-3.81	0.361	2.42	1.64-3.55	0.515
	B	2.04	1.43-2.90		9.42	7.38-12.01		3.35	2.54-4.42		2.04	1.48-2.81
9V	A	1.95	1.36-2.79	0.421	7.12	4.87-10.39	0.078	6.07	4.28-8.61	0.814	5.60	3.91-8.04	0.698
	B	2.38	1.74-3.25		10.41	8.53-12.69		6.36	5.09-7.95		5.16	4.17-6.39
14	A	13.15	9.46-18.28	0.502	27.70	18.72-41.00	0.865	4.44	3.29-6.00	0.716	4.06	3.04-5.44	0.749
	B	11.35	8.62-14.95		28.87	22.24-37.48		4.81	3.65-6.33		3.80	2.81-5.13
18C	A	4.71	3.86-5.73	0.137	15.62	11.72-20.81	0.269	3.56	2.77-4.58	0.528	2.94	2.10-4.10	0.947
	B	3.86	3.25-4.58		19.37	15.10-24.85		3.95	3.23-4.84		2.99	2.27-3.95
19A	A	10.38	8.03-13.42	0.662	29.76	19.34-45.79	0.253	4.15	2.98-5.78	0.519	3.41	2.25-5.16	0.867
	B	9.61	7.57-12.19		42.70	27.60-66.06		4.81	3.59-6.43		3.57	2.62-4.85
19F	A	1.05	0.80-1.37	0.683	3.60	2.41-5.38	0.272	5.31	3.54-7.97	0.766	4.93	3.14-7.75	0.411
	B	0.97	0.74-1.26		4.91	3.40-7.09		5.76	4.04-8.21		3.85	2.67-5.57
23F	A	0.88	0.60-1.28	0.747	2.75	1.71-4.41	0.150	2.30	1.56-3.39	0.401	2.07	1.44-2.97	0.831
	B	0.96	0.68-1.34		4.21	3.02-5.86		2.82	2.13-3.73		2.17	1.64-2.88

	Arm A	Arm B	p-value
Global protection
Pre-vaccination	22/24 (91.7)	26/27 (96.3)	0.595
1 month	23/24 (95.8)	27/27 (100)	0.471
3 years	24/26 (92.3)	33/33 (100)	0.190
5 years	24/26 (92.3)	27/27 (100)	0.236
Global response
1 month	19/24 (79.2)	25/27 (92.6)	0.232
3 years	12/22 (54.5)	20/26 (76.9)	0.131
5 years	12/21 (57.1)	11/20 (55.0)	> 0.99

Variable	Pre-vaccination			1 Month			3 Years			5 Years
Variable	OR	95% CI	p-value	OR	95% CI	p-value	OR	95% CI	p-value	OR	95% CI	p-value
Factors associated with global protection
Arm B	2.12	0.16 to 27.22	0.566	> 999.99	< 0.01 to > 999.99	0.998	> 999.99	< 0.01 to > 999.99	0.995	> 999.99	< 0.01 to > 999.99	0.995
Age ≥ 65 years	> 999.99	< 0.01 to > 999.99	0.999	1.75	< 0.01 to > 999.99	> 0.99	< 0.01	< 0.01 to > 999.99	0.996	< 0.01	< 0.01 to > 999.99	0.996
Female	0.64	0.05 to 8.38	0.735	> 999.99	< 0.01 to > 999.99	0.998	> 999.99	< 0.01 to > 999.99	0.996	> 999.99	< 0.01 to > 999.99	0.996
Gastric (vs. CRC)	> 999.99	< 0.01 to > 999.99	0.999	0.43	< 0.01 to > 999.99	> 0.99	0.66	< 0.01 to > 999.99	> 0.99	> 999.99	< 0.01 to > 999.99	> 0.99
ECOG PS 1 (vs. 0)	< 0.01	< 0.01 to > 999.99	0.999	< 0.01	< 0.01 to > 999.99	0.999	< 0.01	< 0.01 to > 999.99	0.999	< 0.01	< 0.01 to > 999.99	0.999
Higher stage (vs. I-II)	0.55	0.04 to 8.29	0.666	< 0.01	< 0.01 to > 999.99	0.998	< 0.01	< 0.01 to > 999.99	0.998	< 0.01	< 0.01 to > 999.99	0.998
Doublet chemotherapy	2.24	0.14 to 34.81	0.565	< 0.01	< 0.01 to > 999.99	0.998	< 0.01	< 0.01 to > 999.99	0.998	< 0.01	< 0.01 to > 999.99	> 0.99
Factors associated with global response
Arm B	-	-	-	3.92	0.56 to 27.26	0.168	2.79	0.80 to 9.60	0.106	0.82	0.20 to 3.30	0.778
Age ≥ 65 years	-	-	-	> 999.99	< 0.01 to > 999.99	0.999	0.49	0.07 to 3.39	0.472	1.96	0.29 to 13.42	0.495
Female	-	-	-	3.12	0.41 to 23.91	0.275	1.26	0.27 to 5.98	0.769	0.84	0.20 to 3.55	0.815
Gastric (vs. CRC)	-	-	-	3.17	0.11 to 91.06	0.501	> 999.99	< 0.01 to > 999.99	0.999	1.40	0.10 to 19.89	0.804
ECOG PS 1 (vs. 0)	-	-	-	1.75	0.10 to 32.16	0.706	0.76	0.04 to 14.88	0.856	0.54	0.05 to 6.45	0.625
Higher stage (vs. I-II)	-	-	-	0.72	0.10 to 5.14	0.739	1.40	0.30 to 6.57	0.671	0.37	0.09 to 1.56	0.174
Doublet chemotherapy	-	-	-	0.47	0.40 to 5.46	0.546	0.10	0.01 to 1.12	0.062	1.43	0.21 to 9.80	0.714

Table 1. Patients’ characteristics (n=63)

Table 2. Serial changes of GMTs of MOPA

CI, confidence interval; GMT, geometric mean titer; MOPA, multiplex opsonophagocytosis assay.

Table 3. Serial changes of fold increase of MOPA: fold increase in post-vaccination GMTs

CI, confidence interval; GMT, geometric mean titer; MOPA, multiplex opsonophagocytosis assay.

Table 4. GMCs of specific IgG titers

CI, confidence interval; GMC, geometric mean concentration.

Table 5. Global protection and global response by specific IgG titers

Values are presented as number (%).

Table 6. Factors associated with global protection and global response

CI, confidence interval; CRC, colorectal cancer; ECOG PS, Eastern Cooperative Oncology Group performance status; OR, odds ratio.